Michael E. Hurwitz, PhD, MD

Assistant Professor of Medicine (Medical Oncology)

Clinical Interests

  • Adult
  • Urinary Bladder Neoplasms
  • Kidney Neoplasms
  • Medical Oncology
  • Prostatic Neoplasms
  • Testicular Neoplasms

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From physicians only

Patient Care Organizations

Medical Oncology: Subset Medical Oncology Faculty

Cancer Center, Yale: Prostate and Urologic Cancers Program

General Urology

Medical Oncology

Yale Medical Group

Office of Cooperative Research

Board Certifications

  • Medical Oncology AB of Internal Medicine (2004)

Clinical Trials

Conditions Study Title
Prostate A Phase I/II Study of Cabozantinib (XL184) Plus Docetaxel and Prednisone in mCRPC
Prostate VT-464 in Patients W/Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
Bladder WO29636: IMvigor 010 Study: Anti-(PD-L1) Antibody MPDL3280A Treatment vs. Versus Observation
Bladder S1314 (COXEN) with neoadjuvant therapy for localized, muscle invasive bladder cancer
Kidney, Lung, Melanoma, skin, Phase I A phase 1/2 Dose escalation and expansion study of NKTR-214 in patients with adv. or met. tumors
Melanoma, skin Study Using Autologous Tumor Infiltrating Lymphocytes (LN-144) Followed by IL-2 Metastatic Melanoma
Prostate, Phase I EC1169-01:Phase I study of PSA Targeting Tubulysin Conjugate EC1169 in Patients with recurrent mCRPC
Prostate ARMOR3-SV: Phase 3 trial of Galeterone Compared to Enzalutamide AR-V7 M1 CRPC
Bladder, Other Urinary JVDC 05 (RANGE): Ramucirumab Plus Docetaxel in Participants With Urothelial Cancer
Bladder, Other Urinary ML29725: Expanded access program for atezolizumab in metastatic urothelial cancer
Bladder, Lung, Other Digestive Organ, Other Urinary, Stomach, Phase I Ramucirumab + Pembro with Gastric or GEJ Adenocarcinoma, NSCLC or Tcell carcinoma of urothelium
Melanoma, skin Refractory B7-H3-Expressing Neoplasms and Neoplasms whose Vasculature Exhibits B7-H3 Neoplasms
Colon, Melanoma, skin, Phase I Phase 1 Study of CM-24 (MK-6018) in Subjects with Selected Advanced or Recurrent Malignancies
Melanoma, skin, Phase I Varlilumab and Nivolumab in advanced refractory solid tumors
Soft Tissue, Phase I Phase 1 Study of Mogamulizumab (KW-0761) in Combination with MEDI4736 & Mogamulizumab in Combinati
Bladder S1011: Standard or Extended Pelvic Lymphadenectomy in Pts to have Surgery for Invasive Bladder Canc
Bladder, Phase I Novartis BGJ398: A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
Lung, Melanoma, skin Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic
Melanoma, skin Stand Up To Cancer
Other Skin Merkel Cell Carcinoma (MCC) Therapy with MK-3475

Edit this profile

Contact Info

Michael E. Hurwitz, PhD, MD
Patient Care Location
Yale Cancer CenterYale-New Haven Hospital
20 York Street, Ste North Pavilion 4

New Haven, CT 06510
View on map...
Mailing Address
PO Box 208032
New Haven, CT 06520